We are live on ! Find out more
APOPW

Cellect Biotechnology Ltd. Warrants to Purchase ADRs
APOPW

Delisted

APOPW was delisted on the 3rd of August, 2021.

Back to rankings

2 hedge funds and large institutions have $11K invested in Cellect Biotechnology Ltd. Warrants to Purchase ADRs in 2018 Q4 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 2 → 2 (0)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

81% less capital invested

Capital invested by funds: $58K → $11K (-$47K)

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
1
Closed
–
Calls
$6K
Puts
–
Net Calls
+$6K
Net Calls Change
-$10K

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$383

Top Sellers

Rank Fund Capital Flow
1
CH
CVI Holdings
Delaware
-$92
Name Holding Trade Value Shares
Change 		Change in
Stake
Susquehanna International Group
1
Susquehanna International Group
Pennsylvania
$7K +$383 +301 +2%
CH
2
CVI Holdings
Delaware
$4K -$92 -72 -0.6%

APOPW Hedge Fund Activity: Q4 2018 in Review

2 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Cellect Biotechnology Ltd. Warrants to Purchase ADRs (APOPW) for Q4 2018, worth a combined $11K — down 81% from $58K a quarter earlier.

Fund positioning in APOPW was balanced in Q4 2018: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was Susquehanna International Group, adding an estimated $383. The largest seller was CVI Holdings, cutting an estimated $92.

  • 2 institutional investors held Cellect Biotechnology Ltd. Warrants to Purchase ADRs (APOPW) as of Q4 2018, unchanged from Q3 2018.
  • Funds reported $11K of Cellect Biotechnology Ltd. Warrants to Purchase ADRs stock for Q4 2018, down 81% quarter-over-quarter.
  • 0 funds opened new Cellect Biotechnology Ltd. Warrants to Purchase ADRs positions in Q4 2018 and 0 closed out.
  • The largest Cellect Biotechnology Ltd. Warrants to Purchase ADRs buyer in Q4 2018 was Susquehanna International Group, an estimated $383 added.
  • The largest Cellect Biotechnology Ltd. Warrants to Purchase ADRs seller in Q4 2018 was CVI Holdings, an estimated $92 sold.

Based on aggregated 13F filings for Q4 2018.